Home > Market Research > Prescription Medicines > The Pharmaceutical Market: France

Table of Contents

Management Report
Published: January 2010
Pages: 96
Tables: For full details, please email keithw@cmsinfo.com
From: GBP 595.00   Buy Now!
Research from: Espicom
Sector: Prescription Medicines

Espicom’s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, pricing/reimbursement, intellectual property, health facilities and government policy. The report also provides extensive background information, population trends, health status, health expenditure, organisation & administration, hospital services, medical personnel, healthcare development, market access information, trade data for raw materials and finished products and essential industry contacts. Included with the report are 3 free quarterly updated outlook reports, enabling you to keep up to date with market developments for a year.

Overall market growth has been comparatively low at around 5.0% per annum and is expected to average 2.7% in local terms in the medium term with government cost-containment programmes exerting downward pressure on reimbursable products. The hospital market has been much more dynamic with growth rates twice this figure in recent years, although growth rates are now falling due to greater regulatory controls in this sector and fewer innovative drugs coming to market.

The underdeveloped generics market is undergoing rapid expansion boosted by government incentives and the loss of patent protection for several high-volume products. The stagnating OTC market has also started to expand as a result of government moves to end reimbursement for a wide range of products assigned a low medical value rating.

France is the third largest producer of pharmaceuticals in the world, accounting for 7% of global pharmaceutical output. Many multinationals have strategic manufacturing sites in France. However, the country is gradually losing out competitively to other European countries with more attractive business environments, such as Ireland, and to low cost producers in Eastern Europe and South America.

The increasingly competitive business environment has resulted in many smaller independent producers being acquired by multinational groups, recent examples being the acquisition of Fournier Pharma by Solvay of Belgium and the acquisition of Negma-Lerads by Wockhardt of India.

France has also lost ground in the field of pharmaceutical research with the majority of multinationals preferring to concentrate their research efforts in their home country or in the US. Oncology research remains one of the few growth areas, due to the launch of a national cancer plan.

Highly detailed report content

MARKET OUTLOOK
Key national data projections

Pharmaceutical Market Analysis
Current market size
Market structure
Unique 5-year market projections
Imports
Domestic manufacturing
Exports
Research & development

Pharmaceutical regulatory analysis
Including regulation, pricing & reimbursement and intellectual property

Pharmaceutical distribution

Healthcare analysis
Including demographics, healthcare system, health expenditure, healthcare infrastructure and personnel

Top of Page

Table of Contents

EXECUTIVE SUMMARY 1
INTRODUCTION . 2
PHARMACEUTICAL MARKET ANALYSIS . 4
Size . 4
Market Structure . 7
Retail Pharmacy Sector 7
Reimbursable Drugs – Retail Pharmacy Market 12
CNAM Spending on Reimbursable Drugs 15
Hospital Sector 20
Generics Sector 22
OTC Sector . 26
Projections & Outlook . 28
Cost Containment Measures for the Health Sector During 2010 . 28
Market Growth of 2% Forecast for 2009 29
Imports 33
Domestic Manufacturing . 37
Domestic Production . 37
Trade Associations 38
LEEM / LEEM Recherche 38
LIR . 38
GEMME . 38
Local Manufacturers 39
Ipsen 39
Pierre Fabre . 39
Sanofi-Aventis . 40
Sanofi Pasteur . 41
Servier . 41
Multinational Manufacturers 42
AstraZeneca 42
Bristol-Myers Squibb . 42
Eli Lilly 43
GSK . 43
MSD . 43
Pfizer 43
Pharmaceutical Industry Expected to Downsize in Coming Years 43
Exports 44
Research & Development . 48
Sanofi-Aventis . 48
Servier . 49
Pierre Fabre . 49
FRANCE PHARMA OUTLOOK
Pharma Outlook espicom BUSINESS INTELLIGENCE
ii Quarter I 2010
Ipsen 49
LEEM-Recherche 50
PHARMACEUTICAL REGULATORY ANALYSIS . 52
Pharmaceutical Regulation . 52
EU Drug Regulation 52
Centralised Procedure . 52
EMEA . 53
Generic drugs 53
Healthcare Products Safety Agency . 53
Pharmaceutical Registration . 53
Post-marketing surveillance 53
Advertising 54
Pricing & Reimbursement . 54
Pricing . 54
Pricing of reimbursable medicines in the retail pharmacy market 54
Price revisions . 55
Pricing activity 56
State-Industry Framework Agreements 57
Pharmacy margins . 58
Reference pricing (TFR) 58
Pricing of hospital medicines . 58
Reimbursement . 59
Social Security Pharmaceutical Reimbursement Spending Trends . 60
Intellectual Property 60
Supplementary Protection Certificates . 60
Data Exclusivity . 60
PHARMACEUTICAL DISTRIBUTION 61
Wholesaling 61
Distributors 61
Alliance Healthcare 61
CERP . 61
OCP . 61
Phoenix Pharma 62
Retailing 62
HEALTHCARE ANALYSIS 63
Demographics . 63
Population . 63
Birth Rate . 64
Death Rate. 64
Infant Mortality . 64
Maternal Mortality 64
Life Expectancy at Birth . 64
PHARMA OUTLOOK FRANCE
Pharma Outlook espicom BUSINESS INTELLIGENCE
Quarter I 2010 iii
Public Health . 65
Causes of Death 65
Incidence of Communicable Diseases . 66
HIV/AIDS . 66
Hepatitis C / Hepatitis B . 66
Incidence of Non-communicable Diseases 67
Cancer . 68
Cardiovascular Diseases . 69
Diabetes. 69
Hearing Impairment . 70
Mental/ Neurological disorders 70
Musculoskeletal disorders . 71
Renal Disease . 71
Respiratory Disorders 71
Healthcare System 72
National Health Agencies 72
Regional Health Agencies . 72
Public Hospitals . 73
Hospital Restructuring . 73
Regional Health Organisation Plans (SROS) . 73
Ambulatory Services 74
Health Insurance System 75
Health Expenditure . 76
Spending on Pharmaceuticals . 77
Healthcare Infrastructure 78
Public Hospitals . 79
Private Hospital . 79
Non-Profitmaking Hospitals . 79
Commercial Clinics 80
Compagnie Générale de Santé (CGS) . 80
Capio Santé . 80
Médi-Partenaires . 80
Vitalia . 81
Vedici . 81
Regional chains . 81
Inpatient Analysis 81
Surgical Activity . 83
Obstetric Activity . 84
Diagnostic & Therapeutic Activity in the Private Sector . 84
Ambulatory Activity 85
Home Hospitalisation 85
Healthcare Personnel . 86
DIRECTORY 89
FRANCE PHARMA OUTLOOK
Pharma Outlook espicom BUSINESS INTELLIGENCE
iv Quarter I 2010
Government Organisations . 89
Trade Associations . 89
Methodology & Sources . 90
List of Tables
Summary of Key Data Projections, 2010-2015 . 3
Summary of the French Pharmaceutical Market at Retail Prices, 2010 . 4
Sales of Pharmaceuticals for Human Use, 2001-2007 (manufacturers’ prices) 5
Sales of Pharmaceuticals for Human Use, 2001-2007 (Euros Million) . 5
Average Per Capita Consumption of Selected Drug Categories, 2006 6
Top 20 Therapeutic Classes in Retail Pharmacy Drug Market, 2007 9
Top Selling Products’ Share of the Retail Pharmacy Market, 2005-2007 (%) 9
Top 50 Products in Retail Pharmacy Market by Value Ranking, 2007 . 10
Growth in Pharmaceutical Consumption, Reimbursable Products, 2003-2008 12
Reimbursable Pharmaceutical Growth by Principal Factor, 2000-2008 (%) 12
Pharmacy Spending on Reimbursable Products by Reimbursement Status, 2007-2008 . 13
Top Ten Contributors to Increased Spending on Reimbursable Products, 2007 . 13
Top Five Contributors to Reduced Spending on Reimbursable Products, 2008 14
Top Ten Contributors to Reduced Spending on Reimbursable Products, 2007 . 14
CNAM Spending on Reimbursable Drugs, Ambulatory Sector, 2008 15
CNAM Spending Trends on Reimbursable Drugs, by Product Category, 2005-2008 . 15
Pharmaceutical Expenditure Growth by Product Type, 2008 . 18
Top 50 Prescription Products Reimbursed in 2008 . 19
Spending on Specialist Drugs Financed Separately From DRG-Based Fee System, 2006-2008 20
Top 20 Therapeutic Classes in Hospital Drug Market, 2007 . 20
Top 50 Products in Hospital Market by Value Ranking, 2007 . 21
Sales of Reimbursable Generics in Retail Pharmacy Market, 2002-2007 22
Reimbursable Market by Patent Status, 2007 . 22
Top 30 Best selling generics, 2007 23
Generics Penetration Objectives by Volume, 2008 24
Companies Serving the French Generics Market, 2006 25
Market Projections, 2010-2015 . 28
CNAM Spending on Drugs, Ambulatory Sector, January-June 2009 (Euros Million) . 29
Espicom Analysis of the French Pharmaceutical Market, 2010 31
SWOT Analysis of the French Pharmaceutical Market, 2010 32
Pharmaceutical Imports by Category, 2003-2007 (US$ millions) 33
PHARMA OUTLOOK FRANCE
Pharma Outlook espicom BUSINESS INTELLIGENCE
Quarter I 2010 v
Pharmaceutical Import Trends 33
Leading Suppliers of Raw Materials, 2007 (US$000s) . 36
Leading Suppliers of Antisera & Vaccines, 2007 (US$000s) . 36
Leading Suppliers of Medicaments, 2007 (US$000s) 36
Trends in Pharmaceutical Manufacturing Industry, 2000-2006 37
Pharmaceutical Manufacturing Industry by Principal Sector, 2006 . 37
Production of Medicaments and Vaccines for Human Use, 2004-2007 (Euros Million) 37
Members of LEEM Recherche, 2007 38
Members of LIR, 2007 . 38
Members of GEMME, 2007 . 38
Pharmaceutical Exports by Category, 2003-2007 (US$ millions) . 44
Pharmaceutical Export Trends 44
Leading Destinations of Raw Materials, 2007 (US$000s) 47
Leading Destinations of Antisera & Vaccines, 2007 (US$000s) 47
Leading Destinations of Medicaments, 2007 (US$000s) . 47
Pharmaceutical Industry R&D Expenditure, 1995-2006 . 51
Drug Pricing Applications Submitted by Type, 2008 . 56
Average Number of Days Taken to Process First-Time Registrations, 2008 56
Taxes and Other Financial Contributions Imposed on Pharmaceutical Companies, 2000-2007 . 57
Distribution of the Pharmaceutical Market According to Reimbursement Rate, 2007-2008 60
Social Security Drug Reimbursement, 2003-2006 60
Active Pharmacies According to Legal Status, 2001 . 62
Summary of Demographic Data 63
Projected Population, 2010-2015 . 63
Causes of Death, 2006 65
Long-Term Illnesses (New Cases), 2003-2007 67
Projected Growth in Patients with Cancer, Régime Général, 2006-2015 . 68
Projected Growth in Patients with Cardiovascular Disorders, Régime Général, 2006-2015 69
Projected Growth in Patients with Mental/Neurological Disorders, Régime Général, 2006-2015 70
Summary of Healthcare Expenditure 76
Health Expenditure, 2000-2008 76
Projected Health Expenditure, 2010-2015 . 77
Spending Trends on Pharmaceuticals, Ambulatory Sector, 2003-2008 . 77
Pharmaceutical Expenditure by Source of Funding, 2003-2008 (%) 77
Summary of Hospitals & Beds . 78
Selected Medical Equipment Installed at French Hospitals by Sector, 2007 78
Hospital Bed Projections, 2009-2014 78
FRANCE PHARMA OUTLOOK
Pharma Outlook espicom BUSINESS INTELLIGENCE
vi Quarter I 2010
Hospital Activity, 2004-2007 . 82
Hospital Activity by Specialty, 2007 82
Hospital Activity in Short-Stay Units, 2003-2007 . 82
Diagnostic and Therapeutic Procedures Performed in Public and Private Hospitals, 2006 83
Medical Personnel, 2000-2007 . 86
Doctors by Specialty and Sector, 2003-2007 87
Doctors by Sector, 2007 . 88
Projected Number of Physicians, 2010-2015 88
List of Charts
Pharmaceutical Market Growth Rates by Sector, 1997-2007 5
Distribution of the French Pharmaceutical Market by Size of Market Share, 2007 (%) 6
Retail Pharmacy Market by Product Status, 2007, Value % 8
Retail Pharmacy Market by Product Status, 2007, Volume % . 8
Retail Pharmacy Market Growth Rates, 2000-2007 9
Retail Pharmacy Market: Turnover by Therapeutic Area, 2007 (%) 11
Retail Pharmacy Market: Volume by Therapeutic Area, 2007 (%) 11
Distribution of the Reimbursable Market by Age of Presentations, 2008 (%) . 14
Growth in Reimbursable Drug Expenditure, Régime Général, 2002-2009 . 16
Growth in Drug Reimbursements by Category, Régime Général, 2008 (Euros Million) . 17
Growth in Drug Reimbursements by Prescriber, Régime Général, 2008 (Euros Million) . 17
Distribution of the OTC Pharmaceutical Market by Product Status, 2008 (%) 26
Annual Growth Rate in Spending on Reimbursable Drugs, 2000-2009 (%) . 30
Radar Graph of the French Pharmaceutical Market, 2010. 32
Pharmaceutical Imports, 1999-2007 33
Change in Pharmaceutical Imports, 1999-2007 (%) . 34
Pharmaceutical Imports by Category 2007 (%) 34
Leading Suppliers of Pharmaceuticals, 2007 (%) 35
Pharmaceutical Exports, 1999-2007 44
Change in Pharmaceutical Exports, 1999-2007 (%) . 45
Pharmaceutical Exports by Category, 2007 (%) . 45
Leading Destinations of Pharmaceuticals, 2007 46
R&D Employment within the French Pharmaceutical Industry, 1995-2005 (%) . 51
Clinical Trials Initiated, 1995-2006 (%) 51

For full details, please email keithw@cmsinfo.com

Top of Page

Buy now!

PDF single user

 GBP 595.00   

Paper

 GBP 595.00   

Online Access

 GBP 595.00   

Your personal guarantee

Top of Page